Johan Rosell

Survival in prostate carcinoma—Outcomes from a prospective, population‐based cohort of 8887 men with up to 15 years of follow‐up

David Robinson, Gabriel Sandblom, G. Aus, 2005, Cancer.

Reliability of death certificates in prostate cancer patients

Katja Fall, K. Fall, E. Varenhorst, 2008, Scandinavian journal of urology and nephrology.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Didier Frappaz, R. Stupp, C. Marosi, 2012, The Lancet. Oncology.